Therapeutic use of new pharmaceutical preparation containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias (Brevetto)

Type
Label
  • Therapeutic use of new pharmaceutical preparation containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias (Brevetto) (literal)
Anno
  • 2008-01-01T00:00:00+01:00 (literal)
Alternative label
  • Campisi M.1; Renier D.1; Pierimarchi P.2; Serafino A.2 (2008)
    Therapeutic use of new pharmaceutical preparation containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
    (literal)
Titolo
  • Therapeutic use of new pharmaceutical preparation containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Campisi M.1; Renier D.1; Pierimarchi P.2; Serafino A.2 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#proprieta
  • Fidia Farmaceutici S.p.A. (literal)
Http://www.cnr.it/ontology/cnr/brevetti.owl#tipoDiBrevetto
  • Internazionale (literal)
Numero brevetto
  • PD2008A000283 (literal)
Anno di deposito
  • 2008 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1 = Fidia Farmaceutici, Abano Terme (PD) 2 = CNR INMM Roma (literal)
Titolo
  • Therapeutic use of new pharmaceutical preparation containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias (literal)
Abstract
  • The present invention describes the new use in the oncologic field of bioconjugates as differentiating agents obtained by the conjugation between hyaluronic acid (HA) and a chemotherapeutic product (identified hereafter with the trade-name ONCOFID) among which in particular, Irinotecan, Doxorubicin, Paclitaxel, Cis-platinum and 5-fluorouralcyl (5-FU) for treating primary tumors and metastasis. In particular, the biological behaviour is described in terms of action mechanism, efficacy and tolerability of pharmaceutical preparation of derivative of ONCOFID soluble in water. More specifically the invention relates to the surprising biological and pharmacological effect demonstrated by the formulation based on ONCOFID-S (HA-sn38 conjugates) and ONCOFID-D (HA-Doxorubicin conjugates) in promoting the differentiation of tumoral cells towards a untransformed phenotype, compared with the reference drug Irinotecan (or CPT11 whose active form is represented by SN38) and Doxorubicin (literal)
Prodotto di
Autore CNR

Incoming links:


Autore CNR di
Prodotto
data.CNR.it